What Flerie Invest does

Flerie Invest is a Swedish publicly-listed life science investment company headquartered in Stockholm (Skeppsbron 16), founded in 2011 and listed on Nasdaq Stockholm in 2024 via reverse merger with Index Pharmaceuticals Holding AB under the ticker FLERIE. The firm operates as an active, long-term investor that builds and holds a diversified portfolio of pioneering biotech and pharmaceutical companies, organised into two segments: Product Development (approximately 16 clinical-stage companies including Lipum, Prokarium, Xspray Pharma, Empros Pharma, KAHR Medical, Atrogi, Bonsai Biotherapeutics, Microbiotica, Xintela, AnaCardio, Mendus, Geneos Therapeutics, EpiEndo Pharmaceuticals, Vitara Biomedical, Buzzard Pharmaceuticals, Egetis Therapeutics, Amarna Therapeutics, and Strike Pharma) and Commercial Growth (six companies including Symcel, NorthX Biologics, Chromafora, Nanologica, Frontier Biosolutions, and Bohus Biotech). Total fair value of portfolio companies was SEK 2,899M at 31 March 2026, with SEK 2,253M in Product Development and SEK 656M in Commercial Growth as of 30 April 2026.

Flerie's business model is that of a closed-end investment holding company: it does not sell products or services to end customers, generates returns through fair value changes in its portfolio, and monetises for shareholders primarily via NAV growth and dividends from commercial-stage holdings. Capital deployment spans equity, loans (e.g., a SEK 20M facility to Toleranzia in April 2025), underwriting commitments (Nanologica SEK 82.5M rights issue in March 2026), guarantees (SEK 18.9M for Biosergen), and statutory mergers absorbing portfolio companies (Lipum completed March 2026; Biosergen announced June 2026 with a SEK 54.7M valuation at a 31:1 exchange ratio). The company funds its activity through Nasdaq Stockholm equity (86,697,702 ordinary shares after 2026 capital restructuring; share capital SEK 190.7M) and directed issues (SEK 76M in Q1 2026). Net asset value stood at SEK 3,478M at 30 April 2026 (SEK 41.79 per share).

Flerie is led by CEO Ted Fjällman and Deputy CEO/CFO Cecilia Stureborg von Schéele, with Chairman Thomas Eldered acting as principal shareholder through T&M Participation AB and T&M Förvaltning AB. The Board includes Cecilia Edström, Anders Ekblom, Holger Kissel, and Jenni Nordborg. Distribution and marketing to shareholders is conducted via Nasdaq Stockholm settlement through Euroclear Sweden AB, quarterly interim reports and webcast presentations, the annual Biotech Innovation Day in Stockholm, the Flerie Insights podcast/video series featuring external KOLs, press releases, and a corporate LinkedIn presence — positioning Flerie as both an investment vehicle and a thought leader in European life science investing.

Name

Flerie Invest

Legal name

Flerie Invest AB

Website

https://flerie.com

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Flerie Invest is a Swedish Nasdaq Stockholm-listed (FLERIE) life science investment company that builds and holds a diversified portfolio of ~19 biotech and pharmaceutical companies across Product Development and Commercial Growth stages, targeting difficult-to-access private companies for long-term active ownership.

Ownership category

akta.pro rank

Product category

Life Science Investment Management

NAICS

Portfolio Management and Investment Advice (52394), All Other Financial Investment Activities (52399)

SIC

Investment Advice (6282)

akta.pro primary industry

Specialty Real Assets / Niche Strategies (Marinas, Student Housing, Self-Storage, Life Science RE) (FSANAEAO)

akta.pro secondary industries

M&A Advisory (Buy-side/Sell-side) (BPAHADAC), Institutional Consulting RIAs (OCIO/Endowments/Foundations/Pensions) (FSAAACAG)

Keywords

• Life science investing
• Venture capital
• Biotech investment
• Healthcare investment
• Portfolio management

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others

Distribution channels1 record

Marketing channels6 records

Core offering

Flerie Invest is an active long-term life science investment company that builds and manages a diversified portfolio of innovative biotech and pharmaceutical companies. The company provides growth capital, strategic guidance, and network resources to portfolio companies across two categories: Product Development (clinical-stage biotechs) and Commercial Growth (commercial-stage life science companies), investing predominantly in private companies that are difficult to access.

Product overview

Flerie Invest is a life science investment company that operates as a single, unified investment platform rather than a modular product architecture. The company manages a broad and diversified portfolio of innovative companies focused on pioneering pharmaceutical and biotech projects. The portfolio is divided into two main categories: Product Development (biotech companies in various clinical stages such as Lipum, Prokarium, Xspray Pharma, Empros Pharma, KAHR Medical, Atrogi, Bonsai Biotherapeutics, Microbiotica, Xintela, AnaCardio, Mendus, Geneos Therapeutics, EpiEndo Pharmaceuticals, Vitara Biomedical, Buzzard Pharmaceuticals, Egetis Therapeutics, Amarna Therapeutics, and Strike Pharma) and Commercial Growth (companies with commercial-stage products or services including Symcel, NorthX Biologics, Chromafora, Nanologica, Frontier Biosolutions, and Bohus Biotech). Flerie's active ownership model, broad network, and resources are used to support and accelerate the development of portfolio companies' projects, creating value for shareholders.

Differentiator

Problem solved

Functional benefit

Products and services

• Flerie Investment Platform

Quantifiable outcome

• Net asset value per share decreased 3.9% in Q1 2026
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators10 records

Recent moves8 records

Expansion highlights5 records

Regional players

• Kurma Partners: Paris-based European healthcare and biotechnology venture capital firm. Comparable as a European life science investor with active ownership approach, though operating from private funds rather than a listed vehicle.
• HealthCap: Leading Nordic/European life science venture capital firm based in Stockholm, investing in clinical-stage therapeutics and medtech. Direct geographic and sector peer to Flerie's investment focus, though structured as traditional limited-life VC funds rather than a listed holding company.
• Sunstone Capital: Copenhagen-based venture capital firm investing in Nordic life science companies from seed to growth stages. Comparable regional peer focused on the same Nordic life science ecosystem, though operates as traditional VC funds.

Broad incumbents

• EQT Life Sciences: European life science venture capital platform (formerly LSP), part of EQT Group. Comparable as a large-scale European life science investor, though structured within a broader alternatives platform and private funds rather than a listed holding company.
• Arix Bioscience (now Abingworth): London-based life science investment firm previously listed on LSE (now part of Abingworth). Direct comparable as a publicly listed life science investment platform—recently delisted—offering similar exposure to private and public biotech.

Direct peers

• PureTech Health: UK-listed (LSE) clinical-stage biotherapeutics company that operates both as a developer and as a holding entity for a portfolio of founded/incubated life science companies. Directly comparable as a listed life science holding platform with active company-building model.
• HBM Healthcare Investments: Swiss-listed (SIX) investment company focused on private and public healthcare/life science companies globally. Closest analog to Flerie in structure—publicly listed permanent-capital vehicle investing across the life science value chain with active ownership.
• International Biotechnology Trust: UK-listed investment trust specializing in quoted and unquoted biotechnology companies globally. Comparable as a publicly listed vehicle offering diversified biotech exposure with both public and private holdings.
• BB Biotech: Swiss-listed investment company focused on biotechnology equities globally. Comparable as a publicly listed life science investor, though more passive and focused on public equities versus Flerie's private-company tilt.
• Worldwide Healthcare Trust: UK-listed investment trust focused on healthcare and biotechnology equities. Comparable as a public investment vehicle providing investors exposure to a diversified healthcare portfolio, though primarily in public equities rather than private companies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/flerie

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments27 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flerie Invest